NCT07354100招募中1 期
Bifidobacterium Lactulose Optimization in Oncology and Microbiome (BLOOM)
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 55
- 试验地点
- 1
- 主要终点
- Phase 1-
研究概览
简要总结
The purpose of this study is to see if lactulose can improve the effectiveness of immunotherapy in patients with advanced cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Inclusion Criteria Phase I
- •Patients must have a histologically confirmed malignancy that is to receive exclusively ICIs (no chemotherapy or RT in combination) per standard of care during the time in which lactulose will be administered. This includes, but is not limited to, melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, mesothelioma, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, urothelial cancer, MSI/MMRd cancer, cancers with high tumor mutational burden (>=10 muts/mB), esophageal cancer, hepatocellular carcinoma, and renal cell carcinoma. Anti-PD-1 or anti-PD-L-1 therapy combinations with anti-LAG-3 or anti-CTLA-4 combinations are permitted.
- •Age ≥18 years. Because no dosing or adverse event data are currently available on the use of lactulose in combination with ICIs in patients <18 years of age, children are excluded from this study.
- •ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A).
- •Patients must be able to ingest liquids.
- •Inclusion Criteria Phase II
- •Patients must have a histologically confirmed cutaneous or mucosal melanoma. Uveal melanoma is excluded.
- •Measurable disease per RECIST 1.1.32
- •Documented primary or acquired resistance to anti-PD-1 and anti-CTLA4 therapy per SITC guidelines.21 Primary resistance is defined as disease progression after a minimum of 6 weeks of therapy, provided the patient has received at least two full cycles of treatment, and there has been no prior evidence of clinical benefit (partial response, complete response, or stable disease lasting at least 6 months). Acquired resistance is defined as disease progression after an initial clinical benefit while still on therapy or within 12 weeks of discontinuing therapy, provided the patient received at least two cycles and 6 weeks of therapy.
- •Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
- •Planned to receive standard ICI therapy (no RT/ICI or chemotherapy/ICI combinations).
- •Age ≥18 years. Because no dosing or adverse event data are currently available on the use of lactulose in combination with ICIs in patients <18 years of age, children are excluded from this study.
- •ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A).
- •Patients must be able to ingest liquids.
排除标准
- •Exclusion Criteria for Phase I
- •History of allergic reactions attributed to compounds of similar chemical or biologic composition to ICIs or lactulose.
- •Current serious concomitant illnesses include cardiovascular diseases (such as uncontrolled congestive heart failure, hypertension, cardiac ischemia, myocardial infarction, and severe cardiac arrhythmias), bleeding disorders, autoimmune diseases, severe obstructive or restrictive pulmonary diseases, active systemic infections, and inflammatory bowel disorders, including HIV or AIDS-related illnesses or active hepatitis B or C virus.
- •The ongoing use of systemic antibiotics or the previous use of antibiotics in the 2 weeks before enrollment.
- •Presence of a chronic intestinal disease (for example, celiac, or malabsorption) where the frequency of bowel movements would interfere with study assessments.
- •Absence of the large bowel.
- •The presence of absolute contraindications to lactulose administration includes galactosemia or other conditions that necessitate a low intake of galactose.
- •Expected to require any other form of systemic anti-neoplastic therapy while in the study (i.e., chemotherapy or radiation therapy).
- •Symptomatic CNS metastases and/or leptomeningeal involvement. Patients with CNS metastases and/or leptomeningeal involvement may participate if they are clinically stable, as judged by the enrolling investigator.
- •Has an active autoimmune disease or a documented history of autoimmune disease or syndrome that requires systemic steroids or immunosuppressive agents. Patients with vitiligo, type I diabetes, or resolved childhood asthma/atopy are exceptions to this rule.
- •A history of immune-related adverse events to ICIs that precludes the investigator from comfortably re-challenging with ICIs.
- •Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
- •Exclusion Criteria for Phase II
- •Patients with a "currently active" second malignancy other than non-melanoma skin cancers. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are free of disease for ≥ 2 years.
- •History of allergic reactions attributed to compounds of similar chemical or biologic composition to ICIs or lactulose.
- •Current serious concomitant illnesses include cardiovascular diseases (such as uncontrolled congestive heart failure, hypertension, cardiac ischemia, myocardial infarction, and severe cardiac arrhythmias), bleeding disorders, autoimmune diseases, severe obstructive or restrictive pulmonary diseases, active systemic infections, and inflammatory bowel disorders, including HIV or AIDS-related illnesses or active hepatitis B or C virus.
- •The ongoing use of systemic antibiotics or the previous use of antibiotics in the 2 weeks before enrollment.
- •Presence of a chronic intestinal disease (for example, celiac, or malabsorption) where the frequency of bowel movements would interfere with study assessments.
- •Absence of the large bowel
- •The presence of absolute contraindications to lactulose administration includes galactosemia or other conditions that necessitate a low intake of galactose.
- •Expected to require any other form of systemic anti-neoplastic therapy while in the study (i.e., chemotherapy or radiation therapy).
- •Symptomatic CNS metastases and/or leptomeningeal involvement. Patients with CNS metastases and/or leptomeningeal involvement may participate if they are clinically stable, as judged by the enrolling investigator.
- •Has an active autoimmune disease or a documented history of autoimmune disease or syndrome that requires systemic steroids or immunosuppressive agents. Patients with vitiligo, type I diabetes, or resolved childhood asthma/atopy are exceptions to this rule.
- •A history of immune-related adverse events to ICIs that precludes the investigator from comfortably re-challenging with ICIs.
- •Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
研究组 & 干预措施
Phase 1 Arm
Experimental
Patients with solid tumor cancers receiving routine immunotherapy will be enrolled to receive lactulose (10 mg daily).
干预措施: Lactulose (Drug)
Phase 2 Arm
Experimental
o Patients with melanoma receiving routine immunotherapy will be enrolled to receive lactulose (10 mg daily).
干预措施: Lactulose (Drug)
结局指标
主要结局
Phase 1-
时间窗: Baseline to week 3
Change in Bifidobacterium abundance in stool from baseline to week 3.
Overall Response Rate
时间窗: Through study completion, an average of 2 years
Assessment of cancer response based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
次要结局
- Phase 1-Safety and tolerability(3 weeks)
- Phase 1- Effects of lactulose(Baseline to week 3)
- Phase 1- Anti-Tumor Evalution(Baseline to week 3)
- Phase 2- Safety and tolerability(12 weeks)
- Phase 2- Evaluate changes of stool and serum(Baseline to week 12)
- Phase 2- Secondary Gut Evaluation(Baseline to week 3)
- Phase 2- Gut Evaluation(Baseline to week 12)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Inactivated Bacteroides Fragilis for Prevention of Chemotherapy-Induced DiarrheaNCT07309315Shenzhen Hospital of Southern Medical University200
已完成
不适用
Lactobacillus Acidophilus and Limosilactobacillus Reuteri for Acute Diarrhea in ChildrenAcute GastroenteritisInfectious DiarrheaNCT07342088Eskisehir Osmangazi University145
招募中
1 期
Researching Economical Adjuvants to Cancer TherapyNCT07305259Florida State University60
招募中
2 期
Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab – A randomized, placebo-controlled, double-blind Phase II trial (FLORA)Hepatocellular carcinoma2023-506887-15-00Universitaetsklinikum Heidelberg AöR48
已完成
不适用
Topical Lactobacillus Crispatus for Skin Barrier Dysfunction in ObesityNCT07266532Shenzhen People's Hospital98